Biogen
BYOOVIZ
Manufacturer:
Biogen
Name:
BYOOVIZ
HCPCS Code Descriptor:
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
Category:
Q Code
HCPCS:
Q5124
NDC(s):
64406-0019-01
Primary Type:
Opthalmic Biosimilar
Generic/Specialty Status:
LUCENTIS Biosimilar
Route of Administration:
Intraocular
Potential NDC Listing Errors:
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
About:
BYOOVIZ is an Opthalmic Biosimilar drug manufactured by Biogen and administered via the Intraocular route of administration. The Q Code: Q5124 is aligned to the drug BYOOVIZ.
Byooviz is an injection into the eye that is used to treat certain eye disorders and diseases. This medication prevents the formation of new blood vessels under the retina. Byooviz is manufactured by Biogen and is a biosimilar to the medication Lucentis (J2778). This medication is currently aligned to the HCPCS code Q5124 and has been since April 2022. Patient assistance programs for this medication can be found through Biogen Biosimilar Support Services.